ATE487690T1 - 2-aminobicyclo 3.1.0 hexan-2,6- dicarbonsäureesterderivat - Google Patents
2-aminobicyclo 3.1.0 hexan-2,6- dicarbonsäureesterderivatInfo
- Publication number
- ATE487690T1 ATE487690T1 AT04746867T AT04746867T ATE487690T1 AT E487690 T1 ATE487690 T1 AT E487690T1 AT 04746867 T AT04746867 T AT 04746867T AT 04746867 T AT04746867 T AT 04746867T AT E487690 T1 ATE487690 T1 AT E487690T1
- Authority
- AT
- Austria
- Prior art keywords
- hexane
- hydrogen atom
- ester derivative
- aminobicyclo
- acid ester
- Prior art date
Links
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- -1 2-amino-bicyclo [3.1.0] hexane-2,6-dicarboxylic ester Chemical class 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000020925 Bipolar disease Diseases 0.000 abstract 1
- 102000016193 Metabotropic glutamate receptors Human genes 0.000 abstract 1
- 108010010914 Metabotropic glutamate receptors Proteins 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 229910052731 fluorine Chemical group 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/46—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C229/50—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups and carboxyl groups bound to carbon atoms being part of the same condensed ring system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C221/00—Preparation of compounds containing amino groups and doubly-bound oxygen atoms bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
- C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Addiction (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Detergent Compositions (AREA)
- Furan Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003181930 | 2003-06-26 | ||
| JP2003373511 | 2003-10-31 | ||
| JP2004128663 | 2004-04-23 | ||
| PCT/JP2004/009398 WO2005000791A1 (ja) | 2003-06-26 | 2004-06-25 | ２－アミノ－ビシクロ[３．１．０]ヘキサン－２，６－ジカルボン酸エステル誘導体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE487690T1 true ATE487690T1 (de) | 2010-11-15 |
Family
ID=33556154
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04746867T ATE487690T1 (de) | 2003-06-26 | 2004-06-25 | 2-aminobicyclo 3.1.0 hexan-2,6- dicarbonsäureesterderivat |
Country Status (21)
| Country | Link |
|---|---|
| US (5) | US7960579B2 (de) |
| EP (3) | EP2123630B1 (de) |
| JP (1) | JP4792971B2 (de) |
| KR (1) | KR101071507B1 (de) |
| AT (1) | ATE487690T1 (de) |
| AU (2) | AU2004252017B2 (de) |
| BR (1) | BRPI0411823A (de) |
| CA (1) | CA2530706C (de) |
| CY (1) | CY1110997T1 (de) |
| DE (1) | DE602004030007D1 (de) |
| DK (2) | DK1637517T3 (de) |
| ES (1) | ES2394175T3 (de) |
| HK (1) | HK1095318A1 (de) |
| HR (1) | HRP20100619T1 (de) |
| MX (1) | MXPA05013740A (de) |
| NO (1) | NO335004B1 (de) |
| NZ (2) | NZ544131A (de) |
| PL (1) | PL1637517T3 (de) |
| PT (1) | PT1637517E (de) |
| SI (1) | SI1637517T1 (de) |
| WO (1) | WO2005000791A1 (de) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602004030007D1 (en) * | 2003-06-26 | 2010-12-23 | Taisho Pharmaceutical Co Ltd | 2-aminobicyclo 3.1.0 hexan-2,6-dicarbonsäureesterderivat |
| JP5776553B2 (ja) | 2009-11-18 | 2015-09-09 | 大正製薬株式会社 | 酵素を用いた光学活性ビシクロ［３．１．０］ヘキサン誘導体の製造方法 |
| EP2502903A4 (de) | 2009-11-19 | 2013-04-17 | Taisho Pharmaceutical Co Ltd | Verfahren zur herstellung eines 3-alkoxy-2-amino-6-fluorbicyclo-[3.1.0-]hexan-2,6-dicarboxylsäurederivats und eines zwischenprodukts davon |
| WO2012068041A1 (en) | 2010-11-18 | 2012-05-24 | Eli Lilly And Company | 4-SUBSTITUTED-3-BENZYLOXY-BICYCLO[3.1.0]HEXANE COMPOUNDS AS mGluR 2/3 ANTAGONISTS |
| AR083845A1 (es) | 2010-11-18 | 2013-03-27 | Lilly Co Eli | COMPUESTOS 3-FENILSULFANILMETIL-BICICLO[3.1.0]HEXANO 4-SUSTITUIDOS COMO ANTAGONISTAS DE mGluR2/3 |
| WO2013062680A1 (en) * | 2011-10-25 | 2013-05-02 | Braincells, Inc. | Novel compounds and compositions thereof for treating nervous system disorders |
| AR089718A1 (es) | 2012-02-01 | 2014-09-10 | Lilly Co Eli | AGONISTAS DE mGlu2/3 |
| JP5983713B2 (ja) * | 2013-11-29 | 2016-09-06 | 大正製薬株式会社 | 含フッ素アミノ酸のプロドラッグを含有する医薬 |
| FR3026843B1 (fr) * | 2014-10-03 | 2016-11-18 | Univ Pierre Et Marie Curie (Paris 6) | Procede de caracterisation du mecanisme de fissuration d'un materiau a partir de sa surface de rupture |
| KR102444718B1 (ko) | 2016-04-18 | 2022-09-16 | 다이쇼 세이야꾸 가부시끼가이샤 | 아미노산 유도체의 전구약물 |
| JP2020506895A (ja) | 2017-01-17 | 2020-03-05 | ボード オブ レジェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System | インドールアミン２，３−ジオキシゲナーゼおよび／またはトリプトファンジオキシゲナーゼの阻害剤として有用な化合物 |
| KR101877672B1 (ko) | 2017-04-03 | 2018-07-11 | 엘에스산전 주식회사 | Ａｄ컨버터 |
| EP3823604A4 (de) * | 2018-07-17 | 2022-03-16 | Board of Regents, The University of Texas System | Verbindungen als inhibitoren der indolamin-2,3-dioxygenase und/oder tryptophan-dioxygenase |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5750566A (en) * | 1994-08-12 | 1998-05-12 | Eli Lilly And Company | Synthetic excitatory amino acids |
| GB9605429D0 (en) * | 1995-11-16 | 1996-05-15 | Lilly Co Eli | Excitatory amino acid receptor antagonists |
| ZA983930B (en) * | 1997-05-14 | 1999-11-08 | Lilly Co Eli | Excitatory amino acid receptor modulators. |
| JP4194715B2 (ja) * | 1998-08-31 | 2008-12-10 | 大正製薬株式会社 | ６−フルオロビシクロ［３．１．０］ヘキサン誘導体 |
| DE69918136T2 (de) * | 1998-08-31 | 2005-07-07 | Taisho Pharmaceutical Co., Ltd. | 6-Fluorobicyclo[3.1.0]Hexan-Derivate |
| CH694053A5 (de) | 1998-09-03 | 2004-06-30 | Hoffmann La Roche | Verfahren zur Herstellung von 2-Amino-bicyclo[3.1.0]hexan-2,6-dicarbonsäure-Derivaten. |
| WO2002000605A1 (fr) | 2000-06-28 | 2002-01-03 | Taisho Pharmaceutical Co., Ltd. | Nouveaux derives d'acide dicarboxylique |
| WO2002068380A1 (en) * | 2001-02-22 | 2002-09-06 | Eli Lilly And Company | Synthetic excitatory amino acids |
| RU2315622C2 (ru) * | 2001-12-27 | 2008-01-27 | Тайсо Фармасьютикал Ко.,Лтд. | Производные 6-фторбицикло[3.1.0]гексана |
| JP2007063129A (ja) | 2003-06-26 | 2007-03-15 | Taisho Pharmaceut Co Ltd | ２−アミノ−３−アルコキシビシクロ［３．１．０］ヘキサン誘導体 |
| JP4984529B2 (ja) | 2003-06-26 | 2012-07-25 | 大正製薬株式会社 | ２−アミノビシクロ［３．１．０］ヘキサン−２，６−ジカルボン酸誘導体 |
| DE602004030007D1 (en) * | 2003-06-26 | 2010-12-23 | Taisho Pharmaceutical Co Ltd | 2-aminobicyclo 3.1.0 hexan-2,6-dicarbonsäureesterderivat |
-
2004
- 2004-06-25 DE DE602004030007T patent/DE602004030007D1/de not_active Expired - Lifetime
- 2004-06-25 PL PL04746867T patent/PL1637517T3/pl unknown
- 2004-06-25 ES ES09166100T patent/ES2394175T3/es not_active Expired - Lifetime
- 2004-06-25 JP JP2005511127A patent/JP4792971B2/ja not_active Expired - Lifetime
- 2004-06-25 KR KR1020057024818A patent/KR101071507B1/ko not_active IP Right Cessation
- 2004-06-25 SI SI200431569T patent/SI1637517T1/sl unknown
- 2004-06-25 EP EP09166100A patent/EP2123630B1/de not_active Expired - Lifetime
- 2004-06-25 EP EP10181930.8A patent/EP2287147B1/de not_active Expired - Lifetime
- 2004-06-25 MX MXPA05013740A patent/MXPA05013740A/es active IP Right Grant
- 2004-06-25 PT PT04746867T patent/PT1637517E/pt unknown
- 2004-06-25 DK DK04746867.3T patent/DK1637517T3/da active
- 2004-06-25 DK DK09166100.9T patent/DK2123630T3/da active
- 2004-06-25 AT AT04746867T patent/ATE487690T1/de active
- 2004-06-25 US US10/562,018 patent/US7960579B2/en not_active Expired - Fee Related
- 2004-06-25 NZ NZ544131A patent/NZ544131A/xx not_active IP Right Cessation
- 2004-06-25 CA CA2530706A patent/CA2530706C/en not_active Expired - Fee Related
- 2004-06-25 EP EP04746867A patent/EP1637517B1/de not_active Expired - Lifetime
- 2004-06-25 WO PCT/JP2004/009398 patent/WO2005000791A1/ja active Application Filing
- 2004-06-25 AU AU2004252017A patent/AU2004252017B2/en not_active Ceased
- 2004-06-25 NZ NZ580554A patent/NZ580554A/en not_active IP Right Cessation
- 2004-06-25 BR BRPI0411823-5A patent/BRPI0411823A/pt not_active IP Right Cessation
-
2006
- 2006-01-26 NO NO20060428A patent/NO335004B1/no not_active IP Right Cessation
-
2007
- 2007-01-25 HK HK07100898.6A patent/HK1095318A1/xx not_active IP Right Cessation
-
2009
- 2009-07-29 US US12/511,482 patent/US8039647B2/en not_active Expired - Fee Related
- 2009-09-15 AU AU2009217374A patent/AU2009217374B2/en not_active Ceased
-
2010
- 2010-07-30 US US12/847,392 patent/US8076502B2/en not_active Expired - Fee Related
- 2010-11-15 HR HR20100619T patent/HRP20100619T1/hr unknown
- 2010-12-17 CY CY20101101160T patent/CY1110997T1/el unknown
-
2011
- 2011-09-08 US US13/227,942 patent/US8350060B2/en not_active Expired - Fee Related
- 2011-10-07 US US13/269,242 patent/US8258133B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1095318A1 (en) | 2-aminobicyclo(3.1.0)hexane-2,6-dicarboxylic ester derivative | |
| RS107504A (en) | Benzofused heteroaryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compostions including the same, and methods for their use | |
| MY139357A (en) | Novel benzoimidazole derivatives useful as antiproliferative agents | |
| MX2007004183A (es) | Derivados de benzoimidazol utiles como agentes antiproliferacion. | |
| GEP20022676B (en) | 4-Phenyl-Pyridine Derivatives, Method for Their Production and Their Use for Treatment of Disorders Caused by Antagonist of NK-1 Receptors | |
| CY1106645T1 (el) | Παραγωγα 1,2,4 τριαμινοβενζολης χρησιμα για τη θεραπευτικη αντιμετωπιση διαταραχων του κεντρικου νευρικου συστηματος | |
| BRPI0413876A (pt) | tienopiridin-fenilacetamidas e seus derivados úteis como agentes antiangiogênicos | |
| ATE280170T1 (de) | Cyclopenta(b)(1,4) diazepino(6,7,1-hi)indole als 5ht2c antagonisten | |
| MY140525A (en) | Pharmaceutical uses for alpha2delta ligands | |
| NO20055655D0 (no) | Anvendelse av azetidinkarboksamidderivater i terapi | |
| NO20052730L (no) | Aminoalkosyindoler som 5-HT6-reseptorligander for behandling av CNS-lidelser | |
| MXPA05006271A (es) | Metodo para el tratamiento de desordenes del movimiento usando derivados de acido barbiturico. | |
| NZ533358A (en) | 3,4-Dihydro-1H-isoquinolin-2-yl-derivatives for use as NK2 receptor antagonists | |
| SE9702716D0 (sv) | Substituted phenylazacycloalkanes in the treatment of cognitive disorders | |
| AU3231901A (en) | Phenoxyalkylamine derivatives useful as opioid delta receptor agonists | |
| ATE374366T1 (de) | Aminophenoxyacetamid derivate und diese enthaltende pharmazeutische zusammensetzungen | |
| HUP0302255A2 (hu) | Szulfonamidszármazékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| DK1082116T3 (da) | Anvendelse af 4-piperidinmethanolderivater til behandling af neurologiske sygdomme | |
| MX2009005676A (es) | Dialquilamino alquil esteres de pivagabina como medicamentos para el tratamiento de alteraciones del sistema nervioso central. | |
| ATE553087T1 (de) | Therapeutisches mittel gegen chronische obstruktive atemwegserkrankung und verfahren zur behandlung von chronisch obstruktiver atemwegserkrankung mit diesem mittel | |
| NO20053612L (no) | 1,2,4-triaminobenzenderivater nyttige for behandling av forstyrrelser i sentralnervesystemet | |
| ECSP992984A (es) | Derivados de isotiazol utiles como agentes anticancerosos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1637517 Country of ref document: EP |